Impacts of a Brazilian pharmaceutical program on the health of chronic patients

Abstract

OBJECTIVE: To evaluate the impact of the expansion of access to medicines by the Programa Farmácia Popular do Brasil (PFPB – Brazilian Popular Pharmacy Program) on the indicators of hospitalizations and deaths by hypertension and diabetes. METHODS: To estimate the impact of the Brazilian Popular Pharmacy Program, the statistical model of fixed-effect difference in differences was used, considering: the divisions Rede Própria (RP – Proprietary Network) and Rede Conveniada (RC – Partnership Network); the exposure time of the municipality to the program; intramunicipal density, measured by the number of accredited establishments; and the coverage spillover effect into patients from nonparticipating municipalities. Data from 5,566 municipalities were used, for the period from 2003 to 2016, including: (i) administrative records of the PFPB, Sistema de Informações sobre Mortalidade (SIM – Information System on Mortality), and Sistema de Informações Hospitalares (SIH – Hospital Information System); ii) other health data managed by the Departamento de Informática do SUS (DATASUS – Department of Informatics of SUS); iii) sociodemographic data produced by the Brazilian Institute of Geography and Statistics (IBGE); and iv) data from the Relação Anual de Informações Sociais (RAIS – Annual List of Social Information). RESULTS: The expansion of access to medicines for treatment of hypertension and diabetes resulted in a meaningful and statistically significant reduction (p < 0.05) of the number of hospitalizations and deaths by these diseases, in an average annual rate of 27.6% and 8.0%, respectively. The observed impacts were induced by the partnership network, highlighting the density of establishments per 100,000 inhabitants and, above all, the exposure time of the municipality to the program as relevant to the effect. Evidence of a spillover effect and of the maintenance of impacts on different age groups, especially older people, were also observed. CONCLUSIONS: The strategy to expand access to medicines through the PFPB was effective in reducing hospitalizations and deaths by hypertension and diabetes in Brazil during the investigated period. Better understanding the impacts of the program is important to improve the pharmaceutical care policy, to ensure access to cost-effective treatments.

Modelling the effect of compliance with WHO salt recommendations on cardiovascular disease mortality and costs in Brazil

“…While the costs of hypertension drugs have increased, since the creation of the program in 2004, the free or subsidized supply of hypertension drugs has proved to be an effective secondary CVD prevention strategy. As a result, the expansion of access to medicines for the treatment of chronic diseases, such as hypertension, has resulted in an average annual reduction of 27.6% in hospitalizations and 8.0% in deaths by cardiovascular disease in Brazil [ 38 ].…”

Análise documental de aspectos relacionados à prevalência, prevenção, assistência e complicações do diabetes em adultos das unidades federativas brasileiras

“…Outro aspecto de grande relevância para o controle do diabetes e de suas complicações é o acesso aos medicamentos de uso contínuo. Nesse contexto, destaca-se o Programa "Farmácia Popular", que foi criado com o objetivo de melhorar o acesso da população aos medicamentos considerados essenciais, reduzindo o impacto destes gastos no orçamento familiar, e constituindo-se em uma importante medida de saúde pública que pode contribuir para a melhoria da qualidade de vida dos pacientes com diabetes (Almeida et al, 2019). No presente estudo, observou-se que embora a proporção de pessoas que utilizaram medicamentos ou insulina para controle da diabetes tenha aumentado em todas as UF, houve redução na proporção dos que conseguiram o medicamento por meio do programa "Farmácia Popular" na maioria das UF, incluindo todas as das…”

Medication use and obesity in Brazil: results from the National Health Survey

“…This is the case for hypertension, for which at least two types of different drugs are often used in treatment (an anti-hypertensive and a diuretic agent). Another point to bear in mind is that the increase in medications use in Brazil might be attributed to improvements in policy enabling access to drugs through the National Health System ( Sistema Único de Saúde —SUS), at least up until 2015 28 , 29 .…”